ArticleBone marrow transplantation2020
Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.
Erratum issuedOpen access · hybridAbstract readMulticenter Study
In one paragraph
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up.Frontiers in endocrinology · 2022Pooled it
- Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.Blood advances · 2026Trial
- Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.Blood advances · 2025Trial
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Total body irradiation-based conditioning in allogeneic transplantation in patients with hematological malignancies: impact in outcomes by stem-cell source.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.Annals of hematology · 2026Article
- Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukemia (LEA) project.Haematologica · 2025Article
- Long-Term Outcomes of Reduced-Toxicity Conditioning Using 8-Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies.Hematological oncology · 2025Article
- Charting Health Challenges for Digital Preventive Interventions Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia: National Long-Term Follow-Up Survey of Self-Rated Health Outcomes.JMIR formative research · 2024Article
- [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.Frontiers in oncology · 2024Review
- Volumetric modulated arc therapy total body irradiation improves toxicity outcomes compared to 2D total body irradiation.Frontiers in oncology · 2024Article
- Stem cell transplantation for ALL: you've always got a donor, why not always use it?Hematology. American Society of Hematology. Education Program · 2023Review
- Article
- [Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.Blood advances · 2022Article
- Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant.Journal of cancer survivorship : research and practice · 2022Article
- Teenagers and young adults with a past of allogenic hematopoietic stem cell transplantation are at significant risk of chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2022Article
- Review
- Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports).Therapeutic advances in hematology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
53 authors at 20 institutions in 30 countries.
Andre Manfred WillaschDivision for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt, Frankfurt, Germany. andre.willasch@kgu.de.ORCID http://orcid.org/0000-0001-6798-8998
Christina PetersSt. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0369-8515
Petr SedláčekDepartment of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic.
Jean-Hugues DalleDepartment of Pediatric Hemato-Immunology, Hôpital Robert Debré and Université de Paris, Paris, France.ORCID http://orcid.org/0000-0002-8406-0793
Vassiliki Kitra-RoussouStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Thivon and Papadiamantopoulou, Athens, Greece.
Akif YesilipekDepartment of Pediatric Hematology and Stem Cell Transplantation Unit, Medicalpark Antalya Hastanesi, Antalya, Turkey.
Jacek WachowiakDepartment of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
Arjan LankesterDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Arcangelo PreteHematology-Oncology Unit "Lalla Seràgnoli", Department of Pediatrics, University of Bologna, Bologna, Italy.
Amir Ali HamidiehPediatric Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Marianne IfversenDepartment of Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Jochen BuechnerDepartment of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-5848-4501
Gergely KrivánDepartment for Pediatric Hematology and Hemopoietic Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, United St. Istvan and St. László Hospital, Budapest, Hungary.
Rose-Marie HamladjiCentre Pierre et Marie Curie, Service Hématologie Greffe de Moelle, Alger, Algeria.
Cristina Diaz-de-HerediaServicio de Hematologia y Oncologia Pediátricas, Hospital Universitario Vall d'Hebron, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8086-296X
Elena SkorobogatovaBMT Department, Russian Children's Hospital, Moscow, Russia.
Gérard MichelDepartment of Pediatric Hematology and Oncology and Research Unit EA 3279, Timone Enfants Hospital, AP-HM and Aix-Marseille University, Marseille, France.
Franco LocatelliDipartimento di Onco-Ematologia e Terapia Cellulare e Genica, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Alice BertainaDipartimento di Onco-Ematologia e Terapia Cellulare e Genica, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Paul VeysGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Sophie DupontDepartment of Pediatric Hematology and Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Reuven OrDepartment of Bone Marrow Transplantation, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Tayfun GüngörDivision of Stem Cell Transplantation, Children's Research Center (CRC), University Children's Hospital, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-3261-1186
Olga AleinikovaRepublic Clinical Research Centre for Pediatric Oncology and Hematology, Minsk, Belarus.
Sabina SufliarskaBMT Unit, Department of Pediatric Hematology and Oncology, Comenius University Medical School, Limbová, Bratislava, Slovak Republic.
Mikael SundinDivision of Pediatrics, CLINTEC, Karolinska Institutet and Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Jelena RasconCenter of Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania.ORCID http://orcid.org/0000-0003-4420-6943
Ain KaareTartu University Hospital, Tartu, Estonia.ORCID http://orcid.org/0000-0002-3170-1016
Damir NemetDepartment of Haematology, Internal Clinic, University Hospital Centre, Zagreb, Croatia.
Franca FagioliPaediatric Onco-Haematology, City of Science and Health of Turino, Regina Margherita Children's Hospital, Torino, Italy.ORCID http://orcid.org/0000-0002-9257-900X
Thomas Erich KlingebielDivision for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
Jan StyczynskiDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.ORCID http://orcid.org/0000-0002-3158-119X
Marc BieringsBMT-Unit, University Medical Centre Utrecht Pediatrics, Utrecht, The Netherlands.
Kálmán NagyDepartment of Hematology, Child Welfare Center, Borsod County Teaching Hospital, Miskolc, Hungary.
Manuel AbecasisBone Marrow Transplant Program, Instituto Portugues Oncologia, Lisbon, Portugal.
Boris AfanasyevRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Haematology and Transplantation, Saint Petersburg State Medical I.P. Pavlov University, Saint Petersburg, Russia.
Marc AnsariDepartment of Pediatrics, Onco-Hematology Unit, Geneva University Hospital, Geneva University, Geneva, Switzerland.
Kim VettenrantaHospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Amal AlseraihyDepartment of Pediatric Hematology Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Alicja ChybickaDepartment of Bone Marrow Transplantation, Oncology and Hematology, Cape of Hope Medical Center, Wroclaw Medical University, Wroclaw, Poland.
Stephen RobinsonUniversity Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Yves BertrandDepartment of Pediatric Hematology and BMT, IHOP and Claude Bernard University, Lyon, France.
Alphan KupesizDepartment of Pediatric Hematology-Oncology, School of Medicine, Akdeniz University, Antalya, Turkey.
Ardeshir GhavamzadehHematology-Oncology and BMT Research, Shariati Hospital, Tehran, Iran.
Antonio CamposBone Marrow Transplantation Service, Portuguese Institute of Oncology, Porto, Portugal.
Herbert PichlerSt. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-5107-5123
Arnaud DalissierEBMT Paediatric Diseases Working Party, Paris, France.
Myriam LabopinEBMT Paris Study Office, Paris, France.
Selim CorbaciogluDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
Adriana BalduzziBone Marrow Transplantation Unit, Pediatric Department of Milano-Bicocca University, Fondazione Monza e Brianza per il Bambino e la sua Mamma Foundation, Monza, Italy.ORCID http://orcid.org/0000-0002-5879-0610
Jacques-Emmanuel GalimardEBMT Paediatric Diseases Working Party, Paris, France.ORCID http://orcid.org/0000-0001-9102-4427
Peter BaderDivision for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
EBMT Paediatric Diseases Working Party
European Society for Blood and Marrow Transplantation · FRGoethe University Frankfurt · DEBambino Gesù Children's Hospital · ITSt Anna Children's Hospital · ATAix-Marseille Université · FRAkdeniz University · TRAntalya IVF · TRBelarusian Research Center For Pediatric Oncology and Hematology · BYCentre de Recherche Nucléaire d’Alger · DZChildren's Hospital Agia Sophia · GRCliniques Universitaires Saint-Luc · BEComenius University Bratislava · SKCopenhagen University Hospital · DKFirst Pavlov State Medical University of St. Petersburg · RUFondazione Lanza · ITGreat Ormond Street Hospital for Children NHS Foundation Trust · GBHadassah Medical Center · ILInstituto Português de Oncologia Francisco Gentil · PTIPO Porto · PTKarolinska University Hospital · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2-18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective "real-world-practice" study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansRetrospective StudiesSurvival AnalysisTransplantation ConditioningTransplantation, HomologousWhole-Body Irradiation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.